The results of this preclinical study underscore the rationale and effectivity of targeted therapies for BM prevention, a concept that is also supported by recent data of decreased BM development in lung cancer patients receiving the ALK inhibitor alectinib35. This evidence concerns the gene ALK and lung carcinoma.